Searchable abstracts of presentations at key conferences in endocrinology

ea0067o42 | Oral Presentations | EYES2019

Osteoprotegerin and receptor activator of nuclear factor kappa-B ligand levels and their association with BMD in acromegaly

Halupczok-Żyła Jowita , Jawiarczyk-Przybyłowska Aleksandra , Bolanowski Marek

Objective: The purpose of the study was to investigate osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANK-L) levels in acromegaly patients with regard to the disease activity. The associations between OPG, RANK-L and random growth hormone (GH), insulin-like growth factor 1 (IGF-1), lumbar spine (LS) bone mineral density (BMD), femoral neck (FN) BMD were also evaluated.Methods: A study group included 72 patients with acrom...

ea0063gp56 | Acromegaly and GH | ECE2019

Sclerostin and fracture risk assessment in acromegaly

Halupczok-Żyła Jowita , Jawiarczyk-Przybyłowska Aleksandra , Zembska Agnieszka , Bolanowski Marek

Introduction: Sclerostin is well-known as an inhibitor of bone formation but also promotes bone resorption. Acromegaly is a disease characterized by increased bone turnover and higher vertebral fracture risk.Purpose: The aim of the study was to determine sclerostin levels in acromegaly patients with regard to the disease activity. We also evaluated the associations between sclerostin and random growth hormone (GH), insulin-like growth factor 1 (IGF-I), l...

ea0090ep20 | Adrenal and Cardiovascular Endocrinology | ECE2023

Increased sclerostin concentration in patients with primary adrenal insufficiency

Zdrojowy-Welna Aleksandra , Halupczok-Żyła Jowita , Kuliczkowska-Płaksej Justyna , Jawiarczyk-Przybyłowska Aleksandra , Bolanowski Marek

Background: Sclerostin is a protein secreted by osteocytes, that inhibits Wnt/ βcatenin signaling and was suggested to play a role in glucocorticoid-induced osteoporosis in mice. In humans data are inconsistent. Patients with primary adrenal insufficiency need lifelong replacement therapy with glucocorticoids and mineralocorticoids, which may influence their bone quality.Aim: The aim of the study was to evaluate sclerostin concentrations, densitomet...

ea0070aep692 | Pituitary and Neuroendocrinology | ECE2020

Quantitative bone assessment by radiofrequency echographic multi-spectrometry (REMS) in patients with acromegaly – a preliminary study

Halupczok-Żyła Jowita , Rolla Małgorzata , Jawiarczyk-Przybyłowska Aleksandra , Kolackov Katarzyna , Bolanowski Marek

Introduction: Acromegaly is a rare diseaseresulting most commonly from pituitary adenoma. A chronic increase of growth hormone (GH) and insulin-like factor 1 (IGF-1) leads to many systemic complications including osteoporosis and fractures. Radiofrequency echographic multi-spectrometry (REMS) is a new non-ionizing technique to diagnose osteoporosis.Purpose: The objective of the study was to evaluate bone mineral density (BMD) by REMS in patient...

ea0093p10 | Guided Poster Tour 1: Adrenal and Neuroendocrine tumors | EYES2023

The fibroblast growth factor-23/Klotho axis in patients with acromegaly

Halupczok-Żyła Jowita , Jawiarczyk-Przybyłowska Aleksandra , Zembska Agnieszka , Słoka Natalia , Bolanowski Marek

Background: Acromegaly is a rare disease, mostly caused by a GH (growth hormone)-secreting pituitary adenoma. The pathomechanism of bone complications remains not fully explored. The fibroblast growth factor-23 (FGF-23)/Klotho axis regulates phosphate and vitamin D metabolism.Objectives: The study aimed primarily at evaluating FGF-23 and Klotho concentrations with regard to acromegaly activity. The secondary goal was to identify associations between FGF-...

ea0090p164 | Pituitary and Neuroendocrinology | ECE2023

FTO gene polymorphisms and their role in acromegaly

Jawiarczyk-Przybyłowska Aleksandra , Kuliczkowska-Płaksej Justyna , Halupczok-Żyła Jowita , Kolačkov Katarzyna , Zembska Agnieszka , Zdrojowy-Wełna Aleksandra , Bolanowski Marek

Acromegaly is characterized by two-fold higher mortality than in the general population. The leading causes of morbidity and mortality in patients with acromegaly are cardiovascular diseases (CVD). Many population-based studies suggest a role of genetic background in CVD and associated metabolic disturbances. In 2007, FTO (fat mass and obesity associated) gene polymorphisms were discovered. According to a few studies, the polymorphisms of FTO gene are associated with ...

ea0070aep527 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Hormonal function of muscles in acromegaly in relation to metabolic disorders

Mizera Łukasz , Grzegrzółka Jędrzej , Halupczok-Żyła Jowita , Jędrzejuk Diana , Kolackov Katarzyna , Bolanowski Marek , Daroszewski Jacek

Skeletal muscle constitutes the largest endocrine organ in human body through capability of secreting myokines, which biological activity plays a key role in energy homeostasis. Among the myokines irisin (Ir) is of particular interest, considering it’s broad spectrum of protective influence on obesity and metabolic diseases development, determining therapeutical potential of this molecule. Latest studies indicate close interrelations between Ir and myostatin (Mstn), myok...

ea0070aep689 | Pituitary and Neuroendocrinology | ECE2020

Trabecular bone score as a useful tool for assessment of fracture risk in acromegaly

Jawiarczyk-Przybyłowska Aleksandra , Halupczok-Żyła Jowita , Syrycka Joanna , Rolla Małgorzata , Zembska Agnieszka , Kubicka Eliza , Bolanowski Marek

Acromegaly is a rare disease, caused by an excessive secretion of growth hormone (GH), and consequently the insulin like growth factor 1 (IGF-1). Patients with acromegaly have an increased risk of fractures, which might be correlated with insufficient quality of bone. It is known that use of FRAX in acromegaly is not validated, however we do not have other useful tools to assess real risk for fractures. The new valuable tool in the assessment of bone structure is the trabecula...